血液微RNA表达和多形态与老年人认知和生物标志物变化的关联
A Sadlon1, P Takousis, E Evangelou
1Prof. Dr. Robert Perneczky, Division of Mental Health of Older Adults, Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-Universität München, Nußbaumstr. 7, 80336 Munich, Germany, Tel.: +49 89 4400 55772, Fax: +49 89 4400-55448,
The journal of prevention of Alzheimer's disease
|January 17, 2024
概括
六种特定的微RNA (miRNA) 显示出作为检测临床前阿尔茨海默病 (AD) 的早期血液生物标志物的潜力. 这些生物标志物与认知能力下降有关,可能表明早期粉样蛋白和微质通路的参与.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学 是一个
- 生物标志物发现发现
背景情况:
- 在症状出现之前,早期识别患有阿尔茨海默病 (AD) 风险的个体对于有效的预防策略至关重要.
- 老年人微妙的认知衰退可能是神经退行过程的早期指标.
研究的目的:
- 研究特定的微RNAs (miRNAs) 作为血液基生物标志物的潜力,以检测老年人早期认知衰退.
- 探索这些miRNA与阿尔茨海默氏症病理学的关联.
主要方法:
- 对两个观察队列 (CHARIOT-PRO和ADNI) 的横截面分析,涉及超过1600名没有明显临床症状的参与者.
- 在血液样本中对38个优先级miRNA进行定量PCR (qPCR) 分析.
- 功能性丰富分析,与脑脊液 (CSF) 生物标志物 (粉样蛋白-β42,) 的遗传关联研究,以及基因表达分析.
主要成果:
- 六种miRNAs (hsa-miR-128-3p,hsa-miR-144-5p,hsa-miR-146a-5p,hsa-miR-26a-5p,hsa-miR-29c-3p,hsa-miR-363-3p) 在具有较低认知能力的个体中显著下调.
- 途径分析涉及AD早期阶段的亡和炎症.
- 对hsa-miR-29c-3p和hsa-miR-146a-5p基因的遗传变异与CSF粉样蛋白-β42和TREM2水平相关,表明与AD病理学的联系.
结论:
- 已识别的六种miRNA显示出作为阿尔茨海默病亚临床认知缺陷的血液生物标志物具有前途.
- 这些miRNA基因中的多态性表明,在临床前AD阶段,粉样蛋白级联和微质激活之间存在潜在的相互作用.
相关概念视频
Cognitive Development During Adulthood
112
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
112
Alzheimer's Disease: Overview
490
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
490


